Every peptide we analyze.
One reference.

Growth Hormone Releasing Peptide-6

A first-generation hexapeptide ghrelin-receptor agonist that drives a strong growth hormone pulse and a pronounced surge in appetite. GHRP-6 is the most ghrelin-like of the GH secretagogues, which makes it a favorite for hard-gainers and recovery — but also the one most likely to raise cortisol and prolactin at higher doses.

Growth Hormone Releasing Peptide-2

A second-generation hexapeptide ghrelin-receptor agonist that produces a larger growth hormone pulse than GHRP-6 with noticeably less appetite stimulation. GHRP-2 is the workhorse GH secretagogue — more potent than GHRP-6, cleaner on hunger, but still capable of a mild prolactin and cortisol bump at higher doses.

Hexarelin (Examorelin)

A potent hexapeptide GH secretagogue closely related to the GHRP family, notable for the strongest acute GH release of the group and a distinct action at the CD36 receptor that gives it documented cardioprotective effects. Hexarelin's potency comes with faster receptor desensitization, so it is typically cycled rather than run continuously.

Long R3 Insulin-like Growth Factor-1

An engineered analog of IGF-1 with an extended half-life and a substitution that prevents it from being bound and inactivated by IGF binding proteins. The result is a far more potent, longer-lasting signal at the IGF-1 receptor — driving the anabolic and hyperplasic effects that sit downstream of growth hormone.

Melanotan II (MT-II)

A synthetic analog of alpha-MSH that activates the melanocortin receptors, driving skin pigmentation (tanning) through MC1R and sexual arousal and appetite suppression through MC4R. Its dual action — and a tendency to cause nausea and existing-mole darkening — makes individual response highly genotype-dependent.

Kisspeptin-10 (Metastin fragment)

A signaling peptide that sits at the very top of the reproductive hormone axis. Kisspeptin-10 stimulates the hypothalamus to release GnRH, which in turn drives LH and FSH and ultimately testosterone or estrogen — making it a research tool for libido, fertility and hormonal signaling that works by amplifying your own production rather than replacing it.

Follistatin-344 (FST-344)

A naturally occurring protein that binds and neutralizes myostatin and activin — the body's built-in limiters on muscle growth. By sequestering myostatin, Follistatin-344 removes a key brake on hypertrophy, which is why it's one of the most discussed (and still early-stage) research peptides for muscle and recovery.

Insulin-like Growth Factor-1

The primary anabolic mediator of growth hormone. Most of GH's effects on muscle, tissue repair and growth are actually carried out by IGF-1, produced mainly in the liver. Native IGF-1 is short-acting and tightly regulated by binding proteins — making the IGF axis one of the most genetically variable in the body.

PEGylated Mechano Growth Factor

A pegylated form of Mechano Growth Factor — a splice variant of IGF-1 (IGF-1Ec) produced by muscle in response to mechanical overload and damage. MGF's job is to activate satellite cells and kick off repair locally; the PEGylation extends its otherwise very short half-life so the signal lasts long enough to act systemically.

Gonadorelin (GnRH)

A synthetic form of gonadotropin-releasing hormone (GnRH) that directly stimulates the pituitary to release LH and FSH. Because it acts one step below kisspeptin and is given in pulses, gonadorelin is widely used to maintain testicular function and fertility — restarting the downstream hormone cascade without replacing the hormones themselves.

ARA-290 (Cibinetide)

An 11-amino-acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor — the tissue-protective arm of EPO signaling — without raising red blood cell count. ARA-290 is studied mainly for neuropathic pain and inflammation, working by switching cells from an inflammatory state toward repair.

Adipotide (FTPP / Prohibitin-TP01)

An experimental peptide that takes a radically different approach to fat loss — instead of suppressing appetite, it targets the blood vessels that feed white fat tissue, triggering their controlled die-off so fat cells lose their supply. Striking in primate studies, but it never advanced in humans due to kidney-toxicity concerns, so it remains a research-only compound.

ACE-031 (Ramatercept)

A soluble decoy version of the activin receptor type IIB (ActRIIB). ACE-031 acts as a trap — it circulates and binds myostatin and related growth-limiting ligands before they can reach muscle, removing the brake on growth. It reached human trials for muscular dystrophy but was discontinued over vascular safety signals, so it remains research-only.

Nicotinamide Adenine Dinucleotide

A coenzyme present in every cell that sits at the center of energy metabolism and DNA repair. NAD+ levels fall steadily with age, and injectable NAD+ is used in longevity research to restore the substrate that mitochondria and the sirtuin repair enzymes depend on. How much you benefit hinges on the genetics of NAD synthesis and salvage.

Body Protection Compound 157

A 15-amino-acid peptide derived from human gastric juice. The most-researched peptide for tissue repair, gut healing, and injury recovery. Works through nitric oxide signaling, angiogenesis, and collagen stimulation.

Semaglutide (GLP-1 Receptor Agonist)

An FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management (Ozempic, Wegovy). Semaglutide reduces appetite centrally, slows gastric emptying, and improves insulin sensitivity. Notably, it is NOT metabolized by CYP enzymes — response variation is driven by receptor genetics, not liver metabolism.

Tirzepatide (GIP/GLP-1 Dual Receptor Agonist)

An FDA-approved dual agonist that activates BOTH the GIP and GLP-1 receptors (Mounjaro for type 2 diabetes, Zepbound for weight management). The added GIP arm makes it the most potent incretin for weight loss to date — SURMOUNT-1 showed up to ~22.5% body-weight reduction, and the head-to-head SURMOUNT-5 trial beat semaglutide directly. Like semaglutide, it is NOT metabolized by CYP enzymes — response variation is driven by receptor and pathway genetics, not liver metabolism.

Retatrutide (Triple GLP-1 / GIP / Glucagon Receptor Agonist)

An investigational triple-hormone agonist (Eli Lilly, LY3437943) that activates the GLP-1, GIP AND glucagon receptors. In Phase 2 it produced the largest weight loss of any incretin to date — up to ~24% of body weight at 48 weeks, with the curve still falling at study end. The added glucagon arm raises energy expenditure on top of appetite suppression. It is NOT yet approved (Phase 3 TRIUMPH programme ongoing), and like the other incretins it is not CYP-metabolized — response is governed by receptor genetics.

CagriSema (Cagrilintide + Semaglutide)

An investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 agonist) from Novo Nordisk. The amylin arm restores leptin sensitivity while the GLP-1 arm handles appetite and glucose — a different pairing from the GIP-based dual agonists. In the REDEFINE Phase 3 programme it reached ~20.4% body-weight loss (ITT), short of its 25% target. NDA filed; under review in 2026, not yet approved.

Cagrilintide (Long-acting Amylin Analog)

A long-acting amylin receptor agonist from Novo Nordisk — the standalone amylin half of CagriSema. Amylin is a pancreatic hormone that slows gastric emptying, signals fullness, and helps restore leptin sensitivity. As monotherapy it produces meaningful weight loss in early trials; it's most interesting for people whose genetics point to leptin resistance rather than a pure incretin deficit. Investigational, not approved.

MariTide (Maridebart Cafraglutide)

An investigational once-monthly weight-loss drug from Amgen with an unusual design: it's a GLP-1 receptor agonist combined with a GIP receptor ANTAGONIST — the opposite of tirzepatide's GIP agonism. Built as an antibody-peptide conjugate, its real-world edge is convenience: monthly dosing instead of weekly, with sustained weight loss in Phase 2. Currently in the Phase 3 MARITIME programme; not approved.

Survodutide (GLP-1 / Glucagon Dual Agonist)

An investigational GLP-1 and glucagon receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. Like retatrutide it recruits the glucagon arm for energy expenditure, but its standout signal is in the liver — survodutide has produced striking reductions in liver fat and MASH (fatty liver disease), making it the incretin of interest for people with a visceral/metabolic-liver phenotype. In Phase 3 SYNCHRONIZE; not approved.

Tesamorelin (GHRH Analog)

A stabilized growth-hormone-releasing-hormone (GHRH) analog and the only GH-axis peptide with an FDA approval (Egrifta, for visceral fat in HIV-associated lipodystrophy). It stimulates your own pulsatile GH release, which drives IGF-1 and preferential breakdown of visceral (deep belly) fat — backed by real randomized trial data on VAT reduction. Off-label use for visceral fat is common. WADA-banned in sport.

Sermorelin (GHRH 1-29)

The original GHRH analog — the shortest active fragment of growth-hormone-releasing hormone (the first 29 amino acids). It nudges your pituitary to release its own GH in natural pulses, supporting recovery, sleep and body composition. Shorter-acting and gentler than tesamorelin or CJC-1295, with a long safety history but no genotype-stratified evidence. Its FDA approval was withdrawn in 2008 for commercial reasons; it's now widely offered through compounding and anti-aging telehealth.

PT-141 (Bremelanotide)

A melanocortin receptor agonist, FDA-approved as Vyleesi for low sexual desire (HSDD) in premenopausal women and used off-label for libido in both sexes. Unlike Viagra-type drugs that work on blood flow, PT-141 acts centrally in the brain to raise sexual desire itself — a fundamentally different mechanism. Taken on-demand by subcutaneous injection.

Bimagrumab (Anti-ActRII Monoclonal Antibody)

An investigational monoclonal antibody that blocks the activin type II receptor (ActRII), the brake on muscle growth. It does something incretins can't: in trials it reduced fat mass while *increasing* lean muscle. Its real role is as an adjunct to GLP-1/GIP therapy — which strips ~25–30% of lost weight as muscle — to protect lean mass. Clinic-administered IV; not yet approved.

Glycyl-L-Histidyl-L-Lysine Copper Complex

A naturally occurring copper-binding tripeptide that declines with age. GHK-Cu resets gene expression toward a younger pattern, stimulates collagen synthesis, activates antioxidant defenses, and promotes tissue remodeling across skin, bone, and connective tissue.

Thymosin Beta-4 (Fragment)

A 43-amino-acid peptide identical to the active region of Thymosin Beta-4, the most abundant actin-binding protein in the body. TB-500 promotes cell migration, blood vessel formation, and tissue repair systemically — reaching injuries that localized treatments miss.

CJC-1295 (Modified GRF 1-29)

A 29-amino-acid growth hormone releasing hormone (GHRH) analog with enhanced stability. CJC-1295 extends the duration of natural GH pulses without disrupting pulsatile release patterns, providing sustained elevation of growth hormone and IGF-1 for recovery, body composition, and anti-aging.

Ipamorelin Acetate

A pentapeptide ghrelin receptor agonist that triggers clean, selective growth hormone pulses without raising cortisol or prolactin. Ipamorelin is considered the most selective GH secretagogue available, making it the preferred choice for those prioritizing minimal side effects alongside GH optimization.

Semax (ACTH 4-10 Analog with Pro-Gly-Pro)

A synthetic heptapeptide derived from ACTH (4-10) with a C-terminal Pro-Gly-Pro tripeptide extension for stability. Developed in Russia and approved there for stroke recovery and cognitive enhancement. Semax upregulates BDNF, modulates the melanocortin system, and supports neuroplasticity without stimulant-like side effects.

Selank (Tuftsin Analog with Pro-Gly-Pro)

A synthetic heptapeptide derived from the immunopeptide tuftsin, with a Pro-Gly-Pro extension for enzymatic stability. Developed alongside Semax at the Russian Academy of Sciences. Selank modulates GABA-ergic and serotonergic systems to reduce anxiety without sedation, while providing mild cognitive enhancement and immune modulation.

Epitalon (Ala-Glu-Asp-Gly)

A synthetic tetrapeptide based on the natural pineal gland peptide epithalamin. Epithalon activates telomerase, the enzyme that maintains telomere length, potentially slowing cellular aging. Discovered by Professor Vladimir Khavinson, it remains one of the most studied anti-aging peptides in gerontology.

Thymosin Alpha-1 (Thymalfasin)

A 28-amino-acid peptide naturally produced by the thymus gland. Thymosin Alpha-1 is one of the most clinically validated peptides in existence — approved in over 35 countries for hepatitis B/C and as an immune adjuvant. It enhances T-cell maturation, dendritic cell function, and bridges innate and adaptive immunity.

KPV (Lys-Pro-Val)

A tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). KPV retains the potent anti-inflammatory properties of the parent hormone without melanogenic (skin-darkening) effects. It targets gut inflammation through MC1R signaling and NF-kB suppression, making it a focused tool for IBD, colitis, and intestinal permeability.

Glucagon-Like Peptide-2

A 33-amino-acid peptide produced by intestinal L-cells. GLP-2 is the body's primary signal for intestinal growth and repair. Its analog teduglutide (Gattex) is FDA-approved for short bowel syndrome. GLP-2 stimulates crypt cell proliferation, increases villus height, enhances nutrient absorption, and restores gut barrier function.

Advanced Obesity Drug 9604 (hGH Fragment 177-191)

A modified 16-amino-acid fragment of human growth hormone (amino acids 177-191) with a tyrosine substitution. AOD-9604 retains the fat-metabolizing activity of full-length GH without stimulating IGF-1, meaning it promotes lipolysis and inhibits lipogenesis without the growth, insulin resistance, or proliferative risks of HGH.

Mitochondrial Open Reading Frame of the 12S rRNA Type-c

A 16-amino-acid peptide encoded by the mitochondrial genome — one of only a handful of known mitochondrial-derived peptides (MDPs). MOTS-c acts as a retrograde signal from mitochondria to the nucleus, activating AMPK and regulating metabolic homeostasis. It functions as an exercise mimetic, improving insulin sensitivity, fat oxidation, and cellular stress resilience.

SS-31 (Elamipretide / Bendavia / MTP-131)

A synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively targets cardiolipin in the inner mitochondrial membrane. SS-31 stabilizes electron transport chain function, reduces reactive oxygen species production at the source, and prevents mitochondrial permeability transition. Currently in clinical trials for heart failure, mitochondrial myopathy, and age-related mitochondrial dysfunction.

Oxytocin (The Bonding Hormone)

The body's bonding and trust hormone — FDA-approved as Pitocin for labor, and used off-label intranasally for social connection, anxiety and intimacy. Oxytocin acts in the brain to lower social-threat responses and deepen feelings of trust and closeness. Crucially, response is strongly gene-stratified: your OXTR receptor genotype sets how much you actually feel it.

Cerebrolysin (Neuropeptide Preparation)

A mixture of low-molecular-weight neuropeptides and amino acids derived from pig brain, designed to mimic the action of the body's own neurotrophic factors. It has the strongest human clinical evidence of any compound in the cognitive cluster — but for a specific use: acute neuro-injury and dementia, not general cognitive enhancement. Approved across Russia, Europe and Asia for stroke and dementia; not FDA-approved.

LL-37 (Human Cathelicidin Antimicrobial Peptide)

The body's own broad-spectrum antimicrobial peptide — the active fragment of human cathelicidin (the CAMP gene), part of innate immune defense against bacteria, viruses and biofilms. Here's the key insight: your body makes LL-37 in a vitamin-D-dependent way, so for most people the smarter lever is correcting vitamin D to restore endogenous LL-37, rather than injecting an experimental exogenous version with thin safety data.

VIP (Vasoactive Intestinal Peptide)

A 28-amino-acid signaling peptide (studied pharmaceutically as aviptadil) that acts as a powerful endogenous anti-inflammatory and immune regulator. It's been explored intranasally for chronic inflammatory and biotoxin-illness states. The honest framing: VIP suppresses inflammation, so it only makes sense if your inflammation is genuinely over-active — for a genetically 'quiet' immune set-point, there's little to suppress.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)

An angiotensin-IV-derived peptide built to powerfully promote synapse formation by activating the HGF/c-Met system. The marketing claims are dramatic — orders of magnitude more potent than BDNF at building synapses — but the honest position is that those numbers are from lab models, not humans: dihexa has essentially no human clinical data. Experimental, not approved.

DSIP (Delta Sleep-Inducing Peptide)

A nine-amino-acid neuropeptide first isolated for its ability to promote delta-wave (deep) sleep. It's used by people chasing better slow-wave sleep and stress resilience. The honest, gene-aware take: DSIP's deep-sleep advantage is tied to specific adenosine-pathway genetics, so whether it's likely to help *you* depends heavily on your own sleep-architecture genes — for many, it's simply not indicated.

Humanin (Mitochondrial-Derived Peptide)

A small peptide encoded inside mitochondrial DNA — one of the first 'mitochondrial-derived peptides' — that acts as a cytoprotective, metabolic and longevity signal. It's drawn attention because higher humanin levels track with longevity. The crucial genetic nuance: its marquee cognitive/longevity benefit is APOE4-dependent in the research, so the strongest published effect largely disappears in people who don't carry APOE4.